{"id":"W2605003339","doi":"10.1016/j.pupt.2017.03.017","title":"Response to the article “Sorafenib as a potential strategy for refractory pulmonary arterial hypertension”","year":2017,"lang":"en","type":"letter","venue":"Pulmonary Pharmacology & Therapeutics","topic":"Pulmonary Hypertension Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Sunitinib; Medicine; Sorafenib; Refractory (planetary science); Internal medicine; Toxicity; Dosing; Progressive disease; Retrospective cohort study; Progression-free survival; Oncology; Renal cell carcinoma; Surgery; Urology; Overall survival; Disease; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0008383183,0.0009536326,0.001213304,0.0004065072,0.001234241,0.0001486795,0.001127672,0.001311697,0.0007280991],"category_scores_gemma":[0.0000696599,0.0006700631,0.0006898585,0.0002063558,0.0005591877,0.0002062642,0.000360584,0.002592176,0.001070682],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002857868,"about_ca_system_score_gemma":0.001208435,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005361576,"about_ca_topic_score_gemma":0.00000186736,"domain_scores_codex":[0.9941064,0.001019982,0.0007455078,0.001355323,0.001028328,0.001744486],"domain_scores_gemma":[0.9957778,0.0009267741,0.0003823881,0.0016658,0.0006788024,0.0005684294],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.04182741,0.001687547,0.00003863854,0.0001136565,0.001561815,0.09855084,0.00003131987,0.00001593298,0.2826827,6.191978e-7,0.5464389,0.02705061],"study_design_scores_gemma":[0.003365048,0.00255534,0.002175562,0.00009558916,0.003200993,0.0115442,0.00006513349,0.001789286,0.00223496,0.0002161432,0.9721287,0.0006290106],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.1459205,0.003923815,0.00002246554,0.8410838,0.003087822,0.004632306,0.0005841216,0.0001801294,0.000564955],"genre_scores_gemma":[0.2819782,0.001086759,0.0001364167,0.6889117,0.007564538,0.001162277,0.0007807019,0.0002584319,0.01812105],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.4256898,"threshold_uncertainty_score":0.9999848,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07495197995845619,"score_gpt":0.3657364348723154,"score_spread":0.2907844549138592,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}